Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Finished Goods (2016 - 2018)

Apyx Medical's Finished Goods history spans 3 years, with the latest figure at $1.1 million for Q4 2018.

  • For Q4 2018, Finished Goods rose 10.35% year-over-year to $1.1 million; the TTM value through Dec 2018 reached $1.1 million, up 10.35%, while the annual FY2018 figure was $1.1 million, 10.35% up from the prior year.
  • Finished Goods reached $1.1 million in Q4 2018 per APYX's latest filing, up from $1.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.0 million in Q4 2016 to a low of $1.0 million in Q4 2017.
  • Average Finished Goods over 3 years is $1.7 million, with a median of $1.1 million recorded in 2018.
  • Peak YoY movement for Finished Goods: crashed 66.4% in 2017, then increased 10.35% in 2018.
  • A 3-year view of Finished Goods shows it stood at $3.0 million in 2016, then plummeted by 66.4% to $1.0 million in 2017, then rose by 10.35% to $1.1 million in 2018.
  • Per Business Quant, the three most recent readings for APYX's Finished Goods are $1.1 million (Q4 2018), $1.0 million (Q4 2017), and $3.0 million (Q4 2016).